Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…Abstract Number: 0147 • ACR Convergence 2020
The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?
Background/Purpose: The importance of patient-relevant outcomes, such as pain, fatigue and physical functioning, has been long established in the field of rheumatoid arthritis (RA). Patient-reported…Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…Abstract Number: 0360 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Background/Purpose: Several studies have shown an negative association between smoking status and psoriatic arthritis (PsA) clinical outcomes1,2. The German non-interventional study AQUILA provides real-world data…Abstract Number: 0884 • ACR Convergence 2020
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…Abstract Number: 1322 • ACR Convergence 2020
Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: Sleep is an essential health aspect that is often impacted in patients with axial spondyloarthritis (axSpA). This analysis aims to assess the prevalence and…Abstract Number: 1601 • ACR Convergence 2020
Pilot Testing Supports Utility of a Point-of-Care Dashboard to Enhance Patient and Clinician Partnerships in the Management of RA
Background/Purpose: Increasing evidence exists that health outcomes are improved when people living with a chronic condition partner with their clinicians to coproduce their care based…Abstract Number: 1889 • ACR Convergence 2020
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…Abstract Number: 0148 • ACR Convergence 2020
Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study
Background/Purpose: Physicians often consider adverse events when choosing therapies for PsA and RA but may give less attention to other ways in which treatments affect…Abstract Number: 0258 • ACR Convergence 2020
Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
Background/Purpose: Because systemic lupus erythematosus (SLE) is a complex and heterogeneous disease, we have developed a conceptual model that divides SLE activity into two dimensions:…Abstract Number: 0377 • ACR Convergence 2020
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Background/Purpose: Studies indicate that sex (male vs female) is predictive of outcomes with PsA treatments, such as TNF inhibitors (TNFi).1 Tofacitinib is an oral JAK…Abstract Number: 0921 • ACR Convergence 2020
The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
Background/Purpose: The Hospital Anxiety and Depression Scale (HADS) is a screening tool used in patients with different medical conditions. However, its validity, reliability and responsiveness…Abstract Number: 1215 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- Next Page »